High urgency

US-CONGRESS BILLS-119hr2821eh: FDA Modernization Act 3.0

Detected July 22, 2026 · in Dietary-Supplement Labeling (FDA)

The FDA Modernization Act 3.0 introduces mandatory product listing for dietary supplements, new NDI notification requirements, and stricter enforcement on structure function claims and adulteration. It also addresses NAC and CBD status.

Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 22, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All supplement brands, contract manufacturers, private-label sellers, and ingredient suppliers selling in the US should confirm how it applies to their specific situation before acting. There is a time constraint attached: 180 days from enactment (likely early 2026 if passed soon). Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

Mandatory product listing with FDA, updated NDI notification process, clarified structure function claim substantiation, enhanced GMP inspections, and potential reclassification of NAC and CBD.

Who it affects

All supplement brands, contract manufacturers, private-label sellers, and ingredient suppliers selling in the US

What you must do

Register and list all dietary supplement products with FDA within 180 days of enactment; review and update NDI notifications; ensure all structure function claims are substantiated; review GMP compliance.

Deadline

180 days from enactment (likely early 2026 if passed soon)

Source: https://www.govinfo.gov/app/details/BILLS-119hr2821eh

Never miss a change like this again

Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Dietary-Supplement Labeling (FDA)